AU2014391721B2 - Rapid relief of motor fluctuations in Parkinson's Disease - Google Patents

Rapid relief of motor fluctuations in Parkinson's Disease Download PDF

Info

Publication number
AU2014391721B2
AU2014391721B2 AU2014391721A AU2014391721A AU2014391721B2 AU 2014391721 B2 AU2014391721 B2 AU 2014391721B2 AU 2014391721 A AU2014391721 A AU 2014391721A AU 2014391721 A AU2014391721 A AU 2014391721A AU 2014391721 B2 AU2014391721 B2 AU 2014391721B2
Authority
AU
Australia
Prior art keywords
levodopa
patient
administration
dose
fpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014391721A
Other languages
English (en)
Other versions
AU2014391721A1 (en
Inventor
Richard P. Batycky
Martin FREED
Michael M. Lipp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharmaceuticals LLC
Original Assignee
Merz Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharmaceuticals LLC filed Critical Merz Pharmaceuticals LLC
Publication of AU2014391721A1 publication Critical patent/AU2014391721A1/en
Application granted granted Critical
Publication of AU2014391721B2 publication Critical patent/AU2014391721B2/en
Priority to AU2020239754A priority Critical patent/AU2020239754B2/en
Assigned to MERZ PHARMACEUTICALS, LLC reassignment MERZ PHARMACEUTICALS, LLC Request for Assignment Assignors: CIVITAS THERAPEUTICS, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
AU2014391721A 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in Parkinson's Disease Active AU2014391721B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020239754A AU2020239754B2 (en) 2014-04-21 2020-09-24 Rapid Relief of Motor Fluctuations in Parkinson's Disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/034778 WO2015163840A1 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in parkinson's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020239754A Division AU2020239754B2 (en) 2014-04-21 2020-09-24 Rapid Relief of Motor Fluctuations in Parkinson's Disease

Publications (2)

Publication Number Publication Date
AU2014391721A1 AU2014391721A1 (en) 2016-11-03
AU2014391721B2 true AU2014391721B2 (en) 2020-07-16

Family

ID=54332876

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014391721A Active AU2014391721B2 (en) 2014-04-21 2014-04-21 Rapid relief of motor fluctuations in Parkinson's Disease
AU2020239754A Active AU2020239754B2 (en) 2014-04-21 2020-09-24 Rapid Relief of Motor Fluctuations in Parkinson's Disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020239754A Active AU2020239754B2 (en) 2014-04-21 2020-09-24 Rapid Relief of Motor Fluctuations in Parkinson's Disease

Country Status (14)

Country Link
US (2) US20170296498A1 (enExample)
EP (2) EP3134077A4 (enExample)
JP (1) JP2017513866A (enExample)
KR (2) KR20170008754A (enExample)
CN (2) CN113209055A (enExample)
AU (2) AU2014391721B2 (enExample)
BR (1) BR112016024502A8 (enExample)
CA (1) CA2946165C (enExample)
IL (2) IL309959A (enExample)
MX (1) MX2016013741A (enExample)
RU (1) RU2698330C2 (enExample)
SG (1) SG11201608608PA (enExample)
WO (1) WO2015163840A1 (enExample)
ZA (1) ZA201607833B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014074797A1 (en) 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
BR112020013749A2 (pt) * 2018-01-05 2020-12-01 Impel Neuropharma, Inc. dispensação intranasal de pó de levodopa por dispositivo olfativo de precisão
CN112955134A (zh) 2018-07-19 2021-06-11 英倍尔药业股份有限公司 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
US7879358B2 (en) * 2002-03-20 2011-02-01 Alkermes, Inc. Pulmonary delivery for levodopa
WO2014066208A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics, Inc. Levodopa formulations for rapid relief of parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6514482B1 (en) 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
WO2008156586A2 (en) 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
KR20110027817A (ko) * 2008-06-30 2011-03-16 노파르티스 아게 Ｍｇｌｕｒ 조절제를 포함하는 파킨슨병 치료용 조합물
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US8545878B1 (en) * 2012-11-09 2013-10-01 Civitas Therapeutics, Inc. Capsules containing high doses of levodopa for pulmonary use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879358B2 (en) * 2002-03-20 2011-02-01 Alkermes, Inc. Pulmonary delivery for levodopa
GB2454480A (en) * 2007-11-07 2009-05-13 Vectura Group Plc Pulmonary inhalation of levodopa containing compositions in the treatment of Parkinsons disease and other central nervous system disorders
WO2014066208A1 (en) * 2012-10-22 2014-05-01 Civitas Therapeutics, Inc. Levodopa formulations for rapid relief of parkinson's disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anonymous, "Inhaled Levodopa as a Treatment for Intermittent Motor Fluctuations in Parkinson's Disease", (2014-03-01), pages 1 - 2, URL: https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1176, (2017-11-09) *
MARTIN FREED ET AL, NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 82, no. 10, ISSN 0028-3878, (2014-04-08), pages 1 - 2, (2014-04-08) Supplement S7.007 *

Also Published As

Publication number Publication date
AU2014391721A1 (en) 2016-11-03
BR112016024502A2 (pt) 2017-08-15
CN106659685A (zh) 2017-05-10
IL248445A0 (en) 2016-12-29
CA2946165A1 (en) 2015-10-29
KR20170008754A (ko) 2017-01-24
RU2016144340A3 (enExample) 2018-05-22
CN113209055A (zh) 2021-08-06
EP3831375A1 (en) 2021-06-09
CN106659685B (zh) 2021-02-05
RU2016144340A (ru) 2018-05-22
MX2016013741A (es) 2017-04-06
BR112016024502A8 (pt) 2021-06-29
CA2946165C (en) 2022-10-18
US20230053976A1 (en) 2023-02-23
AU2020239754B2 (en) 2022-06-23
EP3134077A1 (en) 2017-03-01
KR20210144946A (ko) 2021-11-30
JP2017513866A (ja) 2017-06-01
US20170296498A1 (en) 2017-10-19
IL309959A (en) 2024-03-01
EP3134077A4 (en) 2017-12-20
SG11201608608PA (en) 2016-11-29
AU2020239754A1 (en) 2021-01-14
ZA201607833B (en) 2018-08-29
RU2698330C2 (ru) 2019-08-26
WO2015163840A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
US12458615B2 (en) Methods for providing rapid relief of motor fluctuations in a Parkinson's disease patient
US20230053976A1 (en) Rapid relief of motor fluctuations in parkinson's disease
AU2020250280B2 (en) Reducing Inter-Patient Variability of Levodopa Plasma Concentrations
JP2019108379A (ja) パーキンソン病の運動症状変動の迅速な緩和
HK40057047A (en) Rapid relief of motor fluctuations in parkinson's disease
HK40071377A (en) Levodopa formulations for rapid relief of parkinson’s disease
HK1212258B (en) Levodopa formulations for rapid relief of parkinson's disease

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MERZ PHARMACEUTICALS, LLC

Free format text: FORMER OWNER(S): CIVITAS THERAPEUTICS, INC.